Viatris

VTRS

Market cap $12.3B

PITTSBURGH , Nov. 24, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in December 2025. The Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 8:30 a.m.

Viatris Inc. ( VTRS ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Scott Smith - CEO & Director Theodora Mistras - Chief Financial Officer Philippe Martin - Chief R&D Officer Corinne Le Goff - Chief Commercial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Hi. Good morning.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

PITTSBURGH , Nov. 13, 2025 /PRNewswire/ --  Viatris Inc.  (Nasdaq: VTRS) today announced that it has been recognized as one of the Fortune World's Best Workplaces™ in 2025 . The list of 25 global leaders was selected from organizations that participated in Great Place To Work's employee survey process, with over 9 million responses representing more than 25 million employees worldwide.

Viatris Inc. ( VTRS ) UBS Global Healthcare Conference 2025 November 11, 2025 8:45 AM EST Company Participants Theodora Mistras - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. My name is Ash Verma, I cover SMID-cap, biotech and spec pharma.

Viatris Inc. ( VTRS ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants William Szablewski Scott Smith - CEO & Director Philippe Martin - Chief R&D Officer Corinne Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer Conference Call Participants Leszek Sulewski - Truist Securities, Inc., Research Division Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Ashwani Verma - UBS Investment Bank, Research Division David Amsellem - Piper Sandler & Co., Research Division Jason Gerberry - BofA Securities, Research Division Presentation Operator Good morning, and welcome to the Viatris Q3 2025 Earnings Call. [Operator Instructions] Please note, this event is being recorded.

Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.

The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Viatris (VTRS) came out with quarterly earnings of $0.67 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.75 per share a year ago.

Drugmaker Viatris beat third-quarter estimates for profit and revenue on Thursday, driven by strong demand for its branded drugs in China and emerging markets.